Form 4: Larimar Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Joseph Truitt acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 13, 2025.
Summary
- On May 13, 2025, Joseph Truitt, a director of Larimar Therapeutics, Inc., acquired 19,000 stock options.
- The options have an exercise price of $1.875.
- The options vest on the earlier of May 13, 2026, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
- The options expire on May 13, 2035.
Sentiment
Score: 5
Explanation: This is a neutral event, simply a disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/13/2025 | Date of earliest transaction: Joseph Truitt acquired 19,000 stock options. |
| 05/13/2026 | Earliest vesting date for the stock options, contingent on continued service. |
| 05/13/2035 | Expiration date of the stock options. |
| 05/14/2025 | Date of signature by Attorney-in-fact. |
Keywords
stock options, director, Larimar Therapeutics, LRMR, Form 4, beneficial ownership, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.